Researcher
Agnieszka Wozniak
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Jul 2006 → 30 Sep 2022
Projects
1 - 9 of 9
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Chicken chorioallantoic membrane (CAM) model as a research tool complementary to patient-derived xenografts (PDX) for preclinical drug testing in sarcomas.From1 Oct 2022 → TodayFunding: BOF - projects
- Preclinical evaluation of innovative cytotoxic drugs for the treatment of soft tissue sarcomaFrom28 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the biology of translocation-related sarcomas and impact on the research for new therapy options.From1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- CYTOTOXIC THERAPY REVISED: EXPLORATION OF INNOVATIVE (PRO)DRUGS IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMAFrom1 Sep 2018 → 25 Oct 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of soft tissue sarcoma and the potential clinical applicationsFrom26 Sep 2017 → 25 Feb 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical outcome, Pathological results and immunohistochemical findings of rare subtypes of soft tissue sarcomasFrom10 Aug 2015 → 30 Sep 2017Funding: Nonprofit institution or equivalents
- Establishment of new research models and in vivo efficacy testing of novel treatment strategies for resistant gastrointestinal stromal tumorsFrom1 Aug 2014 → 19 May 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting soft tissue sarcoma with smart molecules - exploring cytotoxic prodrugs and target-specific inhibitors in patient-derived xenograftsFrom1 Aug 2013 → 30 Nov 2017Funding: Nonprofit institution or equivalents
Publications
31 - 40 of 107
- Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification(2020)
Authors: Agnieszka Wozniak, Daphne Hompes, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pages: 546 - 554 - Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells(2020)
Authors: Maria Debiec-Rychter, Patrick Schöffski, Agnieszka Wozniak
- Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors(2019)
Authors: Annelies Verbiest, Annouschka Laenen, Patrick Schöffski, Maarten Albersen, Agnieszka Wozniak, Benoit Beuselinck
Pages: E981 - E994 - Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts(2019)
Authors: Agnieszka Wozniak, Britt Van Renterghem, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, Patrick Schöffski
- SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma(2019)
Authors: Agnieszka Wozniak, Patrick Schöffski
Pages: 3718 - 3731 - Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing(2019)
Authors: Agnieszka Wozniak, Bram Boeckx, Daphne Hompes, Marguerite Stas, Hazem Wafa, Diether Lambrechts, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pages: 1168 - 1178 - PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors(2019)
Authors: Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pages: 201 - 210 - Anagrelide for Gastrointestinal Stromal Tumor(2019)
Authors: Agnieszka Wozniak, Patrick Schöffski
Pages: 1676 - 1687 - Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors(2019)
Authors: Agnieszka Wozniak, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Pages: 609 - 618 - Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center(2019)
Authors: Agnieszka Wozniak, Daphne Hompes, Raf Sciot, Maria Debiec-Rychter, Patrick Schöffski
Pages: 396 - 403